Telix Pharmaceuticals has entered a strategic clinical collaboration with Varian, a Siemens Healthineers company, to integrate Telix’s theranostic imaging agents into external beam radiation therapy workflows, starting with PSMA-PET for prostate cancer. The partners will explore how Gozellix and Illuccix can support patient selection, adaptive planning via Varian’s Ethos platform, and treatment response monitoring, with a framework that could expand to other PET agents in Telix’s pipeline and future radiopharmaceutical therapeutics.
The signal here is hard to miss: theranostics is moving from the nuclear medicine suite into the command center of radiation oncology. If successful, this could shift referral patterns, expand the clinical footprint of PSMA-PET beyond staging to become a planning and on-treatment decision tool, and position radiation oncologists as orchestrators of precision radiopharmaceutical care. It also reframes Telix’s competitive posture, not just against other PSMA-PET providers, but within a broader ecosystem where treatment planning software, hardware, and molecular imaging converge.
The timing matters. Prostate cancer programs are rapidly adopting PSMA-PET to upstage disease, identify oligometastatic lesions, and personalize therapy intensity, yet the integration into EBRT planning is uneven and often manual. Embedding PSMA-PET into Varian’s adaptive radiotherapy workflow could streamline contouring and dose-escalation strategies, improve metastasis-directed therapy decisions, and create a clearer evidence path for payers linking imaging-informed plans to outcomes. For patients, better target delineation and adaptive response assessment promise fewer misses and less overtreatment. For payers, the value case will hinge on demonstrating that imaging-enabled adaptivity reduces progression and costly interventions, not just that it finds more lesions. For HCPs, especially radiation oncologists and nuclear medicine teams, the collaboration sets the stage for standardized read criteria, multidisciplinary protocols, and new operational pathways that will require coordinated Medical Affairs support.
Commercially, the move nudges PSMA-PET from a diagnostic sale into a software-anchored, workflow-dependent solution — a defensible position that could increase stickiness within Varian’s installed base. It also intensifies the competitive dynamic with Lantheus and other PSMA players by reframing uptake as a function of radiotherapy decisions rather than diagnostic preference alone. For Varian, tighter integration of molecular imaging into adaptive planning responds to growing pressure from competing platforms and aligns with a broader Siemens Healthineers narrative of end-to-end oncology solutions. If expanded to renal cell or neuro-oncology imaging assets in Telix’s pipeline, the collaboration could replicate the model across new indications where dose painting and adaptive strategies are gaining traction.
Execution risk sits squarely in evidence generation, access, and reimbursement. Prospective trials must show that PSMA-guided planning translates to meaningful clinical endpoints, not only detection improvements. Operationally, access to Ga-68 radiopharmacy supply, scheduling synchronization across departments, and reimbursement alignment for imaging in treatment planning will determine real-world adoption. Medical Affairs leaders should prioritize RWE linking adaptive RT decisions to outcomes and cost offsets, while Commercial teams explore contracting models that bundle imaging utilization with software features to derisk payer objections.
The broader trend is clear: as radiopharmaceuticals mature, the battle for control of the patient journey is shifting toward platforms that fuse imaging, planning, and therapy. The critical question now is whether PSMA-PET–enabled adaptive radiotherapy will deliver outcome gains large enough to reset payer expectations — and, if it does, which combination trials of EBRT plus radioligand therapy will follow and who will own that combined standard of care.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
